Evaluating Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Dr. Sharon Choi examines how triplet therapy with androgen deprivation, docetaxel, and an androgen receptor pathway inhibitor fits into metastatic hormone-sensitive prostate cancer management, highlighting trial data, biomarker tools, and patient selection.
Read More